AbbVie axes multi-billion cancer flop Rova-T after another t...

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.

Could phase 3 trial win save AZ's troubled Lupus drug?

AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial

GSK takes option to license hepatitis B RNA drugs from Ionis

GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results.

FDA fast-tracks AZ's Farxiga in potential new CKD indication

The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney

Low-cost polypill could dramatically cut heart attacks, stro...

ViiV's injection still suppresses HIV when taken every two m...

GSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus even if it is taken only six times a year, instead of every month.